knowledge -WSS

knowledge

author：leisure time 2025-09-30 00:33:05 - browse：41

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Doctors' information doesn't help them choose wisely when sick

WSS

Gilead might be held responsible for not developing a drug

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

The dental labor crisis is a moment of opportunity

KalVista pill reduced swelling 'attacks' caused by genetic disease

What we’ve learned from the Aduhelm mess

It's time to retire 'poor historian' from clinicians' vocabularies

explore

knowledge

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Criminal prosecution for violating HIPAA: an emerging threat

Tori Bowie and the unacceptable rates of Black maternal death

To avoid data mishandling cases, universities eye AI and other tools

Bright Health sells Medicare Advantage business to Molina

Solving academic medical centers' existential crisis

What does generative AI mean for health care? We asked experts

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Medical leaders decry Supreme Court decision on affirmative action

Gilead might be held responsible for not developing a drug

focus

PhRMA lawsuit over Medicare drug price negotiation tossed

Military medical care influenced by rank and race, new study finds

PhRMA lawsuit over Medicare drug price negotiation tossed

Venture capitalist Bob Kocher on the state of digital health

Key House Republican on health care plans exit from Congress

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

explore

Wikipedia

focus

hotspot